news
TRV027 to be tested as COVID-19 illness treatment in clinical trial
A clinical trial is set to investigate whether a molecule known as TRV027 is effective at preventing lung damage and the formation of blood clots in COVID-19 patients.
List view / Grid view
Therapeutics
news
Trial for new ibuprofen formulation as COVID-19 treatment launched in UK
A unique formulation of ibuprofen is being tested as a treatment for severe acute respiratory distress syndrome (ARDS), a symptom of COVID-19.
news
New HIV drug formulation approved by FDA to treat paediatric patients
The FDA has approved Tivicay (dolutegravir) and Tivicay PD (dolutegravir) dispersible tablets to treat HIV in children at least four weeks old and weighing at least 3kg.
news
Second of Lilly’s COVID-19 neutralising antibodies begins Phase I trials
The first patient has been dosed in the Chinese Phase I trial of JS016 in healthy people who do not have a COVID-19 diagnosis.
news
Hydroxychloroquine has no benefit to patients hospitalised with COVID-19, finds trial
The RECOVERY trial has stopped enrolment for the hydroxychloroquine arm after data revealed the drug had no meaningful benefit for hospitalised COVID-19 patients.
news
Potential cytokine storm treatment identified for severe COVID-19 patients
Treating COVID-19 patients with respiratory distress with acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor reduced inflammation and improved their breathing within three days.
news
FDA approves Recarbrio for treatment of bacterial pneumonias
Recarbrio (imipenem-cilastatin and relebactam) was approved for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP).
news
Lilly launches Phase I trial of investigational COVID-19 antibody treatment
The enterprise announced the initiation of the LY-CoV555 COVID-19 antibody treatment trial at medical centres across the US.
news
Interim analysis indicates Auxora™ is effective in severe COVID-19 pneumonia patients
Interim results showed Auxora plus standard of care improved time to recovery and reduced ventilator use in patients compared to standard of care alone.
news
COVID-19 convalescent plasma therapy shown to be safe and effective
Scientists reveal 76 percent of critically ill trial participants treated with convalescent plasma are recovering, with almost half now discharged from hospital.
news
60,000 doses of avifavir, a COVID-19 treatment, to be delivered in June
The Russian Direct Investment Fund (RDIF) and the ChemRar Group are to deliver the doses of avifavir, approved in Russia as a COVID-19 therapeutic, to Russian hospitals.
news
Experimental stem cell therapy trial for COVID-19 initiated
Researchers announce the first patient has been dosed in a trial testing remestemcel-L, a stem cell therapy, in severe COVID-19 patients on ventilators.
news
Dose-adjusted chemotherapy regimen effective in Burkitt lymphoma trial
Researchers reveal dose-adjusted (DA) EPOCH-R chemotherapy regimen was effective across all ages of Burkitt lymphoma patients in a Phase II clinical trial.
news
Global COVID-19 hydroxychloroquine trial paused over safety concerns
The WHO has paused the hydroxychloroquine arm of a global trial while it investigates safety concerns highlighted by published studies.
news
Researchers suggest system changes to limit burden of pay-for-delay deals
The changes could prevent anticompetitive practices between branded and generic pharmaceutical manufacturers, lowering drug prices for consumers.
